August 27th 2025
FDA approves updated COVID-19 vaccines for 2025-2026 but limits pediatric access, restricting use to older and high-risk groups.
August 23rd 2025
Immune surveillance study shows pandemic interventions suppressed viral exposure in children, driving post-COVID resurgence and future outbreak risk.
August 22nd 2025
Low-dose methylprednisolone is as effective as high-dose for severe pediatric MPP and has fewer side effects, supporting safer treatment strategies.
August 20th 2025
Biennial HPV testing and higher vaccination rates could help South Korea eliminate cervical cancer up to a decade earlier than current policy.
The baby had mild respiratory distress after delivery and briefly required supplemental blow-by oxygen during transitioning.
American Academy of Pediatrics releases immunization schedule
The AAP recommends that all children aged 6 months to 23 months receive a COVID-19 vaccine, as this group has the highest risk for severe infection.
Can you diagnose this rash in a newborn?
What's the diagnosis?
Adolescent vaccination coverage improves for Tdap and MenACWY; HPV rates remain unchanged
Among adolescents aged 13 to 17, coverage with 1 or more Tdap doses increased from 89% to 91.3% from 2023 to 2024.
Q&A: A deep dive into influenza-associated acute necrotizing encephalopathy
The authors of a recent study on flu-linked necrotizing encephalopathy in children give a deep dive into their findings and the biggest takeaways from the study.
Aligning vaccinations with the start of a new school year
As families prepare for a new school year, pediatricians are essential in helping parents navigate immunization schedules and school requirements and ensuring vaccine confidence.
CDC: Kindergarten vaccination decreases, exemptions increase
New CDC data show fewer kindergartners are fully vaccinated as exemption rates increased during the 2024-2025 school year.
ACIP changes prompt concern as pediatricians prepare for fall vaccine season
Pediatricians are urged to follow 2024 guidelines amid ACIP upheaval, vaccine hesitancy, and access issues as children head back to school.
Larazotide safe, could improve MISC symptoms as adjuvant therapy
“While our study is small, its results are powerful and have implications not only for MIS-C, but potentially for long COVID,” said lead author Lael Yonker, MD.
AAP recommends all healthy children 6 months or older receive influenza vaccine
Of the 253 influenza-related pediatric deaths through June 21, 2025, 42.7% occurred in children without a high-risk medical condition.
New case study, HHS adopts influenza recommendation, and back-to-school vaccination
Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
HHS to remove thimerosal from all influenza vaccines in the US
This week, HHS Secretary Robert F. Kennedy Jr signed the ACIP's recommendation to remove the mercury-based preservative from all influenza vaccines.
Nirsevimab demonstrates high effectiveness against RSV in healthy term infants
Nirsevimab reduced RSV-related illness by up to 98% and lowered hospitalizations and health care use among healthy term infants in a real-world study.
Early antibiotic exposure disrupts infant immune memory, study shows
Early antibiotic exposure disrupts infant immune development by altering gut microbiota, highlighting inosine's potential as a therapeutic target for immune restoration.
Specific groups with chronic conditions who could most benefit from RSV prophylaxis
A newly-published study identified specific groups of higher-risk children that could benefit most from monoclonal antibodies.
US measles cases reach new record high since eradication declaration in 2000
A week into July 2025, the total reported cases in the United States have surpassed the peak of 1274 cases recorded for all 2019.
AAP, other medical societies sue HHS, Robert F. Kennedy Jr. over vaccine practices
Six medical societies, including the American Academy of Pediatrics, are suing the HHS and its Secretary to "defend vaccine policy."
Surge in pediatric Mycoplasma pneumoniae hospitalizations reported in 2024
Mycoplasma pneumoniae caused 1 in 2 pediatric pneumonia hospitalizations in 2024, with sharp increases seen across all age groups, according to a recent CDC MMWR report.
ACIP updates: Committee recommends clesrovimab for RSV, reaffirms routine influenza vaccination
The final recommendation sign off decision will go to HHS secretary Robert F. Kennedy Jr.
ACIP: New members meeting June 25-26; AAP liaisons not participating
The American Academy of Pediatrics will continue to hold its own childhood vaccine schedule, as it has since the 1930s.
PNP Perspective: Focus on the positive outcomes of accepting vaccines
Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her thoughts on how PNPs can implement evidence-based strategies to encourage parents to vaccinate their children.
Weekly review: Clesrovimab for RSV approved, new dupilumab data, and more
FDA expands glecaprevir/pibrentasvir indication for acute hepatitis C down to 3 years of age
Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.
FDA approves clesrovimab to protect infants during first RSV season
The BLA for clesrovimab was based on results demonstrated in the phase 2b/3 CLEVER trial among healthy pre-term and full-term infants.
Renewed focus into Staphylococcus aureus risk in infants, with Aaron Milstone, MD
Aaron Milstone, MD, emphasizes the need for better recognition and prevention of Staphylococcus aureus infections in neonatal intensive care units.
Six-month IXCHIQ chikungunya vaccine data demonstrates sustained antibody levels
Six-month results from the phase 2 VLA1553-221 trial aligned with initial data and demonstrated immune response at day 180 among patients aged 1 to 11 years.
Aaron Milstone, MD, highlights persistent risk of Staphylococcus aureus in premature infants
Aaron Milstone, MD, explains that very low birth weight infants remain disproportionately affected by deadly Staph aureus infections in NICUs.
County-level data set reveals widespread decline in MMR vaccination rates in the United States
The data found complements state- and national-level CDC data, confirming widespread declines in MMR vaccination rates.
CDC: Healthy children can receive COVID-19 vaccine via 'shared clinical decision-making'
In this article, we recap a timeline of recent federal agency changes to routine COVID-19 vaccination intended for the pediatric population.
Expert reactions to new COVID-19 vaccine policies
Federal health agencies have adjusted COVID vaccine guidance, potentially changing eligibility and access for pediatric patients. Experts respond in this article.
Nirsevimab demonstrates sustained efficacy in reducing RSV hospitalizations through 6 months
New phase 3b durability data revealed nirsevimab reduced RSV hospitalizations in infants by 82.7% through 180 days vs no intervention.